Introduction/Background Endometrial cancer (EC) is the most frequent gynecological malignancy in more developed countries. Although the majority of patients are diagnosed at an early stage and cured by hysterectomy, the cancer recurs in about 20% patients with no sign of advanced/metastatic disease with limited response to systemic therapy. Novel biomarkers for EC would be invaluable for preoperative stratification of patients as low/high-risk, detection of primary and recurrent disease and thus enabling personalized therapeutic approaches. Angiogenesis plays an important role in the development and progression of several types of cancer, including EC. This process of is controlled by angiogenic factors (AF). Currently, AF have been studied in some malignancies but their role in EC has not been determined yet. In our study, we analyzed plasma concentration of 20 different AF in patients with the endometrioid type of EC.
Methodology Prospective case - control study of women who underwent surgical treatment at the University Medical Centre Ljubljana (38 patients with endometrioid EC, 38 control patients with prolapsed uterus or myoma). Plasma samples were measured using commercially available kit that enables simultaneous determination of 20 different AF with the Luminex xMAP multiplexing technology.
Results Plasma levels of sTie-2 (soluble angiopoietin-2) showed significantly decreased levels in patients with EC compared to the control group (p<0.05). Tenascin C and angiostatin showed decreased levels in patients with EC and present lymphvascular invasion or deep myometrial invasion (DMI), respectively, while osteopontin levels were increased in patients with EC with DMI, but these differences did not reach statistical significance. Based on different grade of endometriod EC neuropilin showed significant difference.
Conclusion Results of our pilot study indicate that plasma levels of different AF might have a diagnostic and/or prognostic value in endometrioid EC. Further statistical evaluation is currently ongoing.
Disclosure Nothing to disclose.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.